Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.635 USD | +6.17% | -2.38% | +86.36% |
05:21pm | Atossa Therapeutics Doses Last Patient in Phase 2 Karisma-Endoxifen Trial | MT |
May. 13 | Atossa Therapeutics Files $100 Million Mixed-Shelf Offering | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+86.36% | 194M | |
+29.38% | 49.18B | |
+0.84% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.27% | 26.09B | |
-22.71% | 18.71B | |
+8.11% | 13.26B | |
+32.14% | 12.32B | |
-0.68% | 11.99B |
- Stock Market
- Equities
- ATOS Stock
- News Atossa Therapeutics, Inc.
- Maxim Group Adjusts Atossa Therapeutics Price Target to $4 From $7, Maintains Buy Rating